Read more

September 22, 2020
1 min read
Save

ISAR-REACT 5

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ticagrelor (Brilinta, AstraZeneca) vs. prasugrel (Effient, Daiichi Sankyo/Eli Lilly) on clinical outcomes in patients with ACS undergoing a planned invasive strategy.